Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with ß-blockers.
Sci Transl Med
; 9(415)2017 Nov 08.
Article
in En
| MEDLINE
| ID: mdl-29118262
ABSTRACT
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance mediated by T790M-independent mechanisms remains a major challenge in the treatment of non-small cell lung cancer (NSCLC). We identified a targetable mechanism of EGFR inhibitor resistance whereby stress hormones activate ß2-adrenergic receptors (ß2-ARs) on NSCLC cells, which cooperatively signal with mutant EGFR, resulting in the inactivation of the tumor suppressor, liver kinase B1 (LKB1), and subsequently induce interleukin-6 (IL-6) expression. We show that stress and ß2-AR activation promote tumor growth and EGFR inhibitor resistance, which can be abrogated with ß-blockers or IL-6 inhibition. IL-6 was associated with a worse outcome in EGFR TKI-treated NSCLC patients, and ß-blocker use was associated with lower IL-6 concentrations and improved benefit from EGFR inhibitors. These findings provide evidence that chronic stress hormones promote EGFR TKI resistance via ß2-AR signaling by an LKB1/CREB (cyclic adenosine 3',5'-monophosphate response element-binding protein)/IL-6-dependent mechanism and suggest that combinations of ß-blockers with EGFR TKIs merit further investigation as a strategy to abrogate resistance.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Epinephrine
/
Norepinephrine
/
Carcinoma, Non-Small-Cell Lung
/
Adrenergic beta-Antagonists
/
Drug Resistance, Neoplasm
/
Protein Kinase Inhibitors
/
ErbB Receptors
/
Lung Neoplasms
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Sci Transl Med
Journal subject:
CIENCIA
/
MEDICINA
Year:
2017
Type:
Article
Affiliation country:
United States